Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

116.22 +1.41 (+1.23%)
Official Closing Price Updated: 7:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis Ag ADR

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Joblessness Surprise
Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices. 
Via Talk Markets
Panic Attack
The H1 rise in US markets was based on hope for an end to lockdowns. 
Via Talk Markets
Novartis (NVS) Q2 2021 Earnings Call Transcript
NVS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Novartis Posts Q2 Earnings Beat As Sales Pick Up; Reiterates 2021 Guidance
Novartis AG boosted its second-quarter core net income by 20% Y/Y to $3.7 billion, beating market expectations as it kept its 2021 guidance. 
Via Talk Markets
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
Earnings Scheduled For July 21, 2021
Companies Reporting Before The Bell Verizon Communications Inc. (NYSE: VZ) is estimated to report quarterly earnings at $1.29 per share on revenue of $32.68 billion. Seagate... 
Via Benzinga
Novartis Earnings Top, Drug Giant's Stock Eyes Key Level
Novartis earnings beat Q2 views. The drug giant's stock rose slightly, suggesting a move above a key level. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
A Peek Into The Markets: US Stock Futures Up Ahead Of Earnings
Pre-open movers U.S. stock futures traded higher in early pre-market trade as the Dow Jones surged around 550 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
Topics Stocks
Exposures US Equities
Novartis Posts Q2 Earnings Beat As Sales Pick Up; Reiterates 2021 Guidance
Novartis AG (NYSE: NVS) boosted its second-quarter core net income by 20% Y/Y to $3.7 billion, beating market expectations as it kept its 2021 guidance. Earnings:... 
Via Benzinga
Topics Earnings
Exposures Financial
AbbVie: High Yield At A Low P/E
Over the first half of this year, pharmaceutical giant AbbVie has traded in a narrow range while meme stocks, cryptocurrencies, and other get-rich-quick schemes have diverted investor attention away... 
Via Talk Markets
Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients
Incyte Corporation (NASDAQ: INCY) has announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM... 
Via Benzinga
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,... 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Dialing For Stocks
Thanks to Fed Chairman Powell, markets brushed off worrying about inflation today. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Cowen Initiates Coverage On Molecular Partners With Price Target Of $50
Cowen & Co initiated coverage on Molecular Partners (NASDAQ: MOLN) with an Outperform rating and a Price Target of $50, implying an upside potential of... 
Via Benzinga
Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159
Celldex Therapeutics Inc (NASDAQ: CLDX) got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold... 
Via Benzinga
Recovery Friday
The big winners this week were Financials. 
Via Talk Markets
Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant
Molecular Partners AG (NASDAQ: MOLN) reported on the clinical progress of its antiviral candidate, ensovibep, as part of a presentation with its partner Novartis... 
Via Benzinga
Exposures COVID-19
Pot Stocks Down In June - Remain +29.6% YTD
There are four cannabis/cannabis-related pot stock categories which I use to provide the clearest overview of the cannabis stock sector that is available anywhere. Below is a comparison of how each... 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Novartis Looks To Enter mRNA Technology, Says Chairman: Reuters
Novartis AG (NYSE: NVS) could get into the field of messenger ribonucleic acid (mRNA) technology, reported Reuters, citing Chairman Joerg Reinhardt in a newspaper... 
Via Benzinga
Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut
Just shy of a full year after emerging from stealth mode, Aerovate Therapeutics Inc (NASDAQ: AVTE) is listing onto NASDAQ with an upsized offering. The company ... 
Via Benzinga
Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Is This Chinese Biopharma Stock Still a Buy?
The pharmaceutical company had a solid first quarter and boasts a nice pipeline. 
Via The Motley Fool
Week In Review: Insilico Closes $255 Million Round For AI Drug Discovery/Development
Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. The company is developing its own products and... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Crazy Thursday
Today the US stock market went ballistic probably because of a higher joblessness level than expected. 
Via Talk Markets
Reconsidered Boom
The US markets tried to repeat the big rise from yesterday, and appears to have succeeded. 
Via Talk Markets
The First Day Of Summer And Prime Day
The bull is back in business today. 
Via Talk Markets
Novartis Touts More Positive Zolgensma Data In Spinal Muscular Atrophy Patients
Novartis AG (NYSE: NVS) announced new data from the completed two-copy cohort of Phase 3 SPR1NT trial of Zolgensma (onasemnogene abeparvovec), gene therapy for... 
Via Benzinga
Continued Uncertainty
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
Dreary Day
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.